Medpace Recognized with WCG Pinnacle Award for Professionalism and Communication in Site Relationships

Medpace Recognized with 2025 WCG Pinnacle Award for Professionalism and Communication in Site Relationships 

Medpace is proud to be recognized a 2025 WCG Pinnacle Award recipient for Leadership in Professionalism and Communication, based on results from the WCG CenterWatch Global Site Relationship Survey, one of the most comprehensive evaluations of Sponsor and CRO performance from the perspective of investigational sites worldwide. 

This inaugural award highlights the critical role of site relationships in driving successful clinical trials, and positions Medpace among the most trusted global partners in clinical development. With feedback from over 12,000 global site professionals, Medpace was recognized for consistently high ratings in professionalism, communication, and responsiveness—three of the most influential factors in ensuring quality trial conduct and reliable execution.  

Trusted by Sites. Chosen by Sponsors. Proven in Performance.

For biopharma Sponsors, effective site relationships are a core operational driver. Poor communication, delayed responses, or inefficient workflows at the site level can derail timelines and compromise data integrity. Medpace’s recognition through the WCG Pinnacle Award is a measurable indicator of the company’s strength in this crucial area.  

Globally, select sites that consistently meet or exceed expectations for quality, speed, and collaboration earn the designation of a Medpace Flagship Site. Medpace also maintains preferred partnerships with key site networks, holding regular alignment meetings to assess study load and continuously improve collaboration. These efforts ensure that Sponsors benefit from faster startup timelines, reliable enrollment, and consistent, high-quality data across regions. 

Medpace’s model of embedding medical and operational experts across every phase of clinical development enables deeper site engagement and streamlined communication, especially in complex or global trials. This approach has translated into faster startup timelines, stronger site performance, and consistent trial quality—key performance indicators for Sponsors seeking reliable CRO partnerships.  

Explore the full 2025 WCG CenterWatch Global Site Relationship Survey results at www.wcgclinical.com.  

Why Sponsors Choose Medpace

As clinical trials grow in complexity and scope, Sponsors need more than transactional vendors. They need CRO partners who are trusted by investigative sites, embedded in science, and accountable for operational and clinical outcomes. Medpace’s recognition in the 2025 WCG Pinnacle Awards reflect the trust we’ve earned across the global site landscape—and the confidence Sponsors place in us to deliver.  

Our extensive, global experience encompasses Phase I-IV trials in over 45 countries, in a full range of oncologic and hematologic indications and therapies from classic multi-cytotoxic agents to cutting edge and targeted therapies.